Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Non-small Cell Lung Cancer (NSCLC) makes up about 85% of lung cancer cases, mainly adenocarcinoma and squamous cell carcinoma. Recently, PD-1 inhibitors have become crucial in NSCLC treatment, significantly enhancing survival for some. However, side effects, like skin reactions and hematotoxicity, limit their use, with drug-induced TEN and immunotherapy-induced agranulocytosis as severe adverse effects.

Case Presentation

Herein, we have reported the case of a 75-year-old male diagnosed with metastatic Lung Squamous cell Carcinoma (LUSC) in the left lung. He received first-line treatment with one cycle of tislelizumab in combination with nab-paclitaxel and carboplatin, after which he developed Toxic Epidermal Necrolysis (TEN) and granulocytopenia. To address these two serious immune-related Adverse Events (irAEs), the patient was administered methylprednisolone in combination with gamma globulin for TEN and dexamethasone in combination with G-CSF for agranulocytosis. Antibiotics were also administered according to the patient’s medication regimen. After treatment, the patient recovered and was discharged from the hospital. It was also noted that the lung tumor condition improved.

Conclusion

Effective management of severe immune-related side effects from tislelizumab, including TEN and agranulocytosis, can be partly achieved through steroids, gamma globulin, G-CSF, and antibiotics. This strategy not only alleviates these adverse effects, but also potentially improves tumor conditions, highlighting the crucial role of vigilant monitoring and management in immunotherapy.

© 2025 The Author(s). Published by Bentham Science Publisher. 
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863297885240604111018
2024-06-20
2025-09-01

  • From This Site

    /content/journals/cds/10.2174/0115748863297885240604111018
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cds/20/3/CDS-20-3-14.html?itemId=/content/journals/cds/10.2174/0115748863297885240604111018&mimeType=html&fmt=ahah

References

  1. DahanR. SegaE. EngelhardtJ. SelbyM. KormanA.J. RavetchJ.V. FcyRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis.Cancer Cell201528328529510.1016/j.ccell.2015.08.004 26373277
     [Google Scholar]
  2. ZhangT. SongX. XuL. The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions.Cancer Immunol. Immunother.20186771079109010.1007/s00262‑018‑2160‑x 29687231
     [Google Scholar]
  3. SpainL. DiemS. LarkinJ. Management of toxicities of immune checkpoint inhibitors.Cancer Treat. Rev.201644516010.1016/j.ctrv.2016.02.001 26874776
     [Google Scholar]
  4. PanY. HanH. LabbeK.E. ZhangH. WongK.K. Recent advances in preclinical models for lung squamous cell carcinoma.Oncogene202140162817282910.1038/s41388‑021‑01723‑7 33707749
     [Google Scholar]
  5. RenS. ChenJ. XuX. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial.J. Thorac. Oncol.202217454455710.1016/j.jtho.2021.11.018 34923163
     [Google Scholar]
  6. HerbstR.S. GiacconeG. de MarinisF. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC.N. Engl. J. Med.2020383141328133910.1056/NEJMoa1917346 32997907
     [Google Scholar]
  7. Paz-AresL. LuftA. VicenteD. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer.N. Engl. J. Med.2018379212040205110.1056/NEJMoa1810865 30280635
     [Google Scholar]
  8. WangJ. LuS. YuX. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer.JAMA Oncol.20217570971710.1001/jamaoncol.2021.0366 33792623
     [Google Scholar]
  9. KanjiS. MorinS. AgtarapK. Adverse events associated with immune checkpoint inhibitors: Overview of systematic reviews.Drugs202282779380910.1007/s40265‑022‑01707‑1 35416592
     [Google Scholar]
  10. KramerR. ZarembaA. MoreiraA. Hematological immune related adverse events after treatment with immune checkpoint inhibitors.Eur. J. Cancer202114717018110.1016/j.ejca.2021.01.013 33706206
     [Google Scholar]
  11. TurgemanI. WollnerM. HassounG. BonsteinL. Bar-SelaG. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.Anticancer Drugs201728781181410.1097/CAD.0000000000000520 28574922
     [Google Scholar]
  12. FinkelI. SternschussM. WollnerM. Immune-related neutropenia following treatment with immune checkpoint inhibitors.J. Immunother.2020432677410.1097/CJI.0000000000000293 31498181
     [Google Scholar]
  13. HaanenJ.B.A.G. CarbonnelF. RobertC. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol.2017284Suppl. 4iv119iv14210.1093/annonc/mdx225 28881921
     [Google Scholar]
  14. KumarV. ChaudharyN. GargM. FloudasC.S. SoniP. ChandraA.B. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy.Front. Pharmacol.201784910.3389/fphar.2017.00049 28228726
     [Google Scholar]
  15. ZhuJ ChenG HeZ Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. EClinMed2021 3710.1016/j.eclinm.2021.10095134386743
     [Google Scholar]
  16. WangL.L. NoeM.H. MichelettiR.G. Prevalence of leukopenia and associated outcomes in patients with stevens-johnson syndrome/toxic epidermal eecrolysis.JAMA Dermatol.2022158101212121410.1001/jamadermatol.2022.3011 35976636
     [Google Scholar]
  17. KinoshitaM. OgawaY. HamaN. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis.Sci. Transl. Med.20211360010.1126/scitranslmed.aax2398 34193610
     [Google Scholar]
  18. AngC.C. TayY.K. Hematological abnormalities and the use of granulocyte‐colony‐stimulating factor in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis.Int. J. Dermatol.201150121570157810.1111/j.1365‑4632.2011.05007.x 22098009
     [Google Scholar]
/content/journals/cds/10.2174/0115748863297885240604111018
Loading
Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review
Curr Drug Saf 20, 361 (2025); https://doi.org/10.2174/0115748863297885240604111018
/content/journals/cds/10.2174/0115748863297885240604111018
/content/journals/cds/10.2174/0115748863297885240604111018
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): agranulocytosis; case report; immune-related adverse events; immunotherapy; lung squamous cell carcinoma; Tislelizumab; toxic epidermal necrolysis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test